The outlook for elimination of the scourge of cervical cancer is bright, because we now have the tools to achieve this goal. In recent years human papillomavirus (HPV) vaccination in high-income countries has resulted in dramatic decreases in HPV infection and associated cervical disease. If all countries with a substantial burden of disease
introduce the vaccine nationally, we can protect the vast majority of women and girls most at risk. For women who are beyond the vaccination target age, progress has been made in screening and treatment for cervical precancer, but we must accelerate this momentum to reduce incidence and mortality worldwide to the very low rates found in wealthier countries. Human and financial resources must be increased and directed to programs that follow best practices and reach all women, including the marginalized or dis advantaged. Seven key actions are recommended. Now is the time for action at national, regional, and global levels.
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Cervical cancer; HPV vaccine; Low-and middle-income countries; Prevention; Screening United Nations Secretary-General Ban Ki-moon's 2016 call to eliminate cervical cancer was a critical moment showing how far we have comeand how far we still have to go. prophylactic strategies to deploy-vaccination for young adolescents and screening and preventive treatment for adult women.
In the 10 years since HPV vaccines were introduced in highincome countries, we have seen dramatic decreases in HPV infection and associated cervical disease among vaccinated populations, and even among the unvaccinated (through herd immunity, where coverage is high). As coverage increases, we anticipate significant impact from the vaccine, since it can protect against 70%-90% of cervical cancer and several other HPV-related cancers. If all countries with a substantial burden of disease introduce the vaccine nationally, we can go a long way toward protecting the vast majority of those women and girls most at risk. Unfortunately, only about 3% of eligible girls worldwide are estimated to have been vaccinated against HPV so far, despite that more than 80 countries have officially incorporated the vaccine into their national immunization programs. 5 Countries with high HIV prevalence, which could benefit most from HPV vaccination because of the increased risk for cervical cancer among HIV-positive women, 6 are among those with very low coverage rates to date.
There also is good news for women who are beyond vaccination target age when HPV vaccines become available in their communities.
New, relatively simple and affordable cervical cancer screening and preventive treatment strategies are being adopted by many countries that previously had no such programs. 7 In most cases, treatment of women with precancer is relatively low cost, especially compared to the cost of invasive cancer treatment (which, in far too many cases, is not widely accessible). More women are now being screened and treated than ever before, but global coverage, again, is estimated to be very low.
While this Supplement focuses on prevention of disease, it should be noted that expanding services to treat invasive cancer could also save many lives.
In spite of low coverage with vaccination and screening/preventive treatment, there is positive momentum and cause for optimism. In just the past few years: IARC, UNAIDS, UNFPA, UNICEF, and UN Women. 13 Just getting started as this Supplement goes to press, this partnership also seeks to scale up prevention, screening, and treatment, with a focus on lowand lower-middle-income countries.
Many leaders see cervical cancer prevention and control as a human rights issue. They are quick to point out that progress in prevention will contribute not only to the Sustainable Development Goals for good health and well-being, but also to goals that seek to increase gender equity. 11 Women play a critical role in sustainable development. When they are able to reach their full potential, women contribute to thriving families, build more resilient communities, are stalwart stewards of the environment, and are powerful drivers of economic development. It will be difficult for countries to achieve Overall, we need to:
1. Harness the tools and best practices we already have in hand and scale them up into national programs;
2. Seek synergies with other primary healthcare services, including integration with HIV services;
3.
Ensure seamless linkages between screening and treatment of precancer so that no woman is lost to follow-up;
4.
Negotiate affordable vaccine pricing for non-Gavi countries and develop innovative financing mechanisms for essential screening and precancer treatment supplies, equipment, and training;
5.
Work with all relevant stakeholders to ensure public and policy maker confidence in HPV vaccination and new screening and preventive treatment modalities in order to achieve maximal vaccine and screening coverage;
6. Capture reliable data on cervical cancer prevention services in national health information systems so that progress against essential indicators can be tracked nationally and globally and so that resources can be allocated where they are needed most;
7.
Where resources permit, improve access to definitive cancer treatment and effective palliative care for those who did not benefit from prevention efforts.
The end of cervical cancer is now in sight. With funding already available to vaccinate an additional 40 million girls by 2020, we have a huge opportunity to reduce the number of women dying from cervical cancer.
Similar resources must also be mobilized for screening. We call on the new UN Secretary-General, donors, and all national leaders-particularly those in low-and middle-income countries-to support this call for action, to drive national political will, and encourage increased UN coordination and collaboration. Now is the time to prevent the unrelenting pain and isolating stigma of cervical cancer. Now is the time for action at national, regional, and global levels. We can do this and we must.
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